Cargando…

SIL1 functions as an oncogene in glioma by AKT/mTOR signaling pathway

PURPOSE: SIL1 is a ubiquitous protein localized to the endoplasmic reticulum and functions as a cochaperone of BiP. Previous studies have shown that function loss of SIL1 is often associated with neurological diseases, such as Marinesco-Sjögren Syndrome. However, no studies have investigated the fun...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Hao, Xu, Shangchen, Zhang, Rui, Xin, Tao, Pang, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033116/
https://www.ncbi.nlm.nih.gov/pubmed/29997438
http://dx.doi.org/10.2147/OTT.S167552
_version_ 1783337638952960000
author Xu, Hao
Xu, Shangchen
Zhang, Rui
Xin, Tao
Pang, Qi
author_facet Xu, Hao
Xu, Shangchen
Zhang, Rui
Xin, Tao
Pang, Qi
author_sort Xu, Hao
collection PubMed
description PURPOSE: SIL1 is a ubiquitous protein localized to the endoplasmic reticulum and functions as a cochaperone of BiP. Previous studies have shown that function loss of SIL1 is often associated with neurological diseases, such as Marinesco-Sjögren Syndrome. However, no studies have investigated the function of SIL1 in tumors. In this study we aim to reveal functions of SIL1 and the underlying mechanisms in glioma. MATERIALS AND METHODS: First, by searching on Gene Expression Profiling Interactive Analysis, we examined SIL1 expression and prognostic value in glioblastoma multiforme (GBM) and brain lower grade glioma (LGG). Immunohistochemical analysis (IHC) was also performed to determine the endogenic SIL1 level. Cell counting kit-8 (CCK8) and clone formation assays were used to detect cell proliferation of U251 cells. Cell migration was detected by transwell assay and cell cycle and apoptosis were detected by flow cytometry. Western blot was performed to determine protein expression. RESULTS: We found that the expression of SIL1 was increased by approximately 1.5-fold in GBM and 1.3-fold in LGG compared with normal controls (P<0.05) and negatively correlated with patients’ survival. IHC revealed that SIL1 expression was significantly higher in glioma tissues than that in paracancerous tissues (P<0.05). Glioma patients with high SIL1 expression accounted for 65.79% (25/38) of total samples and SIL1 expression significantly increased in grade IV glioma compared to grades I–III (P=0.026). Suppression of SIL1 expression led to significant inhibition of U251 cell proliferation. Transwell assay showed that cell migration of U251 was significantly inhibited by siSIL transfection, with an inhibitory rate reaching 69%. Flow cytometry detection showed that siSIL1 could induce apoptosis of U251 cells and upregulated the expression of the pro-apoptotic protein Bax and Caspase3-P17. However, siSIL1 transfection had no effect on the cell cycle. Mechanism studies demonstrated that siSIL1 transfection led to inactivation of AKT/mTOR signaling pathway, including decreased phosphorylation of AKT and mTOR without affecting protein expression, as well as decreased expression of the downstream effector p70S6K. CONCLUSION: Downregulation of SIL1 inhibited the progression of glioma by suppressing the AKT/mTOR signaling pathway.
format Online
Article
Text
id pubmed-6033116
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-60331162018-07-11 SIL1 functions as an oncogene in glioma by AKT/mTOR signaling pathway Xu, Hao Xu, Shangchen Zhang, Rui Xin, Tao Pang, Qi Onco Targets Ther Original Research PURPOSE: SIL1 is a ubiquitous protein localized to the endoplasmic reticulum and functions as a cochaperone of BiP. Previous studies have shown that function loss of SIL1 is often associated with neurological diseases, such as Marinesco-Sjögren Syndrome. However, no studies have investigated the function of SIL1 in tumors. In this study we aim to reveal functions of SIL1 and the underlying mechanisms in glioma. MATERIALS AND METHODS: First, by searching on Gene Expression Profiling Interactive Analysis, we examined SIL1 expression and prognostic value in glioblastoma multiforme (GBM) and brain lower grade glioma (LGG). Immunohistochemical analysis (IHC) was also performed to determine the endogenic SIL1 level. Cell counting kit-8 (CCK8) and clone formation assays were used to detect cell proliferation of U251 cells. Cell migration was detected by transwell assay and cell cycle and apoptosis were detected by flow cytometry. Western blot was performed to determine protein expression. RESULTS: We found that the expression of SIL1 was increased by approximately 1.5-fold in GBM and 1.3-fold in LGG compared with normal controls (P<0.05) and negatively correlated with patients’ survival. IHC revealed that SIL1 expression was significantly higher in glioma tissues than that in paracancerous tissues (P<0.05). Glioma patients with high SIL1 expression accounted for 65.79% (25/38) of total samples and SIL1 expression significantly increased in grade IV glioma compared to grades I–III (P=0.026). Suppression of SIL1 expression led to significant inhibition of U251 cell proliferation. Transwell assay showed that cell migration of U251 was significantly inhibited by siSIL transfection, with an inhibitory rate reaching 69%. Flow cytometry detection showed that siSIL1 could induce apoptosis of U251 cells and upregulated the expression of the pro-apoptotic protein Bax and Caspase3-P17. However, siSIL1 transfection had no effect on the cell cycle. Mechanism studies demonstrated that siSIL1 transfection led to inactivation of AKT/mTOR signaling pathway, including decreased phosphorylation of AKT and mTOR without affecting protein expression, as well as decreased expression of the downstream effector p70S6K. CONCLUSION: Downregulation of SIL1 inhibited the progression of glioma by suppressing the AKT/mTOR signaling pathway. Dove Medical Press 2018-07-02 /pmc/articles/PMC6033116/ /pubmed/29997438 http://dx.doi.org/10.2147/OTT.S167552 Text en © 2018 Xu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Xu, Hao
Xu, Shangchen
Zhang, Rui
Xin, Tao
Pang, Qi
SIL1 functions as an oncogene in glioma by AKT/mTOR signaling pathway
title SIL1 functions as an oncogene in glioma by AKT/mTOR signaling pathway
title_full SIL1 functions as an oncogene in glioma by AKT/mTOR signaling pathway
title_fullStr SIL1 functions as an oncogene in glioma by AKT/mTOR signaling pathway
title_full_unstemmed SIL1 functions as an oncogene in glioma by AKT/mTOR signaling pathway
title_short SIL1 functions as an oncogene in glioma by AKT/mTOR signaling pathway
title_sort sil1 functions as an oncogene in glioma by akt/mtor signaling pathway
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033116/
https://www.ncbi.nlm.nih.gov/pubmed/29997438
http://dx.doi.org/10.2147/OTT.S167552
work_keys_str_mv AT xuhao sil1functionsasanoncogeneingliomabyaktmtorsignalingpathway
AT xushangchen sil1functionsasanoncogeneingliomabyaktmtorsignalingpathway
AT zhangrui sil1functionsasanoncogeneingliomabyaktmtorsignalingpathway
AT xintao sil1functionsasanoncogeneingliomabyaktmtorsignalingpathway
AT pangqi sil1functionsasanoncogeneingliomabyaktmtorsignalingpathway